You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Owen Mumford has acquired the exclusive rights to Atomo's CE-marked HIV tests and will bring them to market in Europe under the Simplitude brand.
The initial focus will be on Zika and chikingunya, and will leverage iBio's antigen and antibody manufacturing capabilities for product prototype development.
At least one HIV self-test from a competitor could reach the global market this year. In addition, the company is in the midst of a strategic review.
The findings run counter to historical data and may provide fodder to reconsider current guideline recommendations on surveillance of colorectal cancer patients.
The partners will combine Chembio's DPP technology and biomarkers developed at Mass General for diagnostic tests for typhoid and febrile illness.
The companies will work together on the development and commercialization of companion diagnostics that use Abcam antibodies.
The test was previously cleared to run on the Sofia platform and can rapidly differentiate human IgM and IgG antibodies to Borrelia burgdorferi from serum and plasma specimens.
The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.
Danish IVD firm BioPorto will distribute a version of its NGAL Test for use on the Cobas c 501/
The company's HIV testing revenues were up 24 percent year over year, while HCV testing revenues plummeted 68 percent.